Sacubitril/valsartan was recently FDA approved to reduce morbidity and mortality in patients with reduced ejection fraction heart failure
This medication is the first in the class of neprilysin inhibitors
Sacubitril/valsartan could replace angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) as the standard of care in heart failure